{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', '7.1.2.', 'Liver Chemistry Stopping Criteria', 'Liver chemistry stopping and increased monitoring criteria have been designed to', 'assure participant safety and evaluate liver event etiology (in alignment with the FDA', 'premarketing clinical liver safety guidance).', 'ttp://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid', 'ances/UCM174090.pdf', 'Discontinuation of study intervention for abnormal liver tests is required when:', 'a participant meets one of the conditions outlined in Section 11.9.1', 'when in the presence of abnormal liver chemistries not meeting protocol-specified', 'stopping rules, the investigator believes study intervention discontinuation is in', 'the best interest of the participant.', 'Liver Safety Required Actions and Follow up Assessments can be found in Section 11.9.', '7.1.3.', 'Temporary Discontinuation', 'Participants may have a temporary interruption to their study intervention for', 'management of toxicities. Such interruption of study intervention does not require', 'withdrawal from the study. However, consultation with the Medical Monitor is required.', '7.1.4.', 'Restart', 'If participant meets liver chemistry stopping criteria do not restart the participant with', 'study intervention unless:', 'ViiV Healthcare Safety and Labelling Committee (VSLC) approval is granted,', 'Ethics and/or IRB approval is obtained, if required, and', 'Separate consent for treatment restart is signed by the participant.', 'Refer to Section 11.9.2 for full guidance.', '7.2.', 'Withdrawal from the Study', 'Participants may be prematurely discontinued from the study for any of the', 'following reasons:', 'Participant or Investigator non-compliance;', 'A participant may withdraw from the study at any time at his/her own request, or may', 'be withdrawn at any time at the discretion of the investigator for safety, behavioral,', 'compliance or administrative reasons. This is expected to be uncommon;', '54']['2017N331008_00', 'CONFIDENTIAL', '208090', 'If the participant withdraws consent for disclosure of future information, the sponsor', 'may retain and continue to use any data collected before such a withdrawal of', 'consent;', 'If a participant withdraws from the study, he/she may request destruction of any', 'samples taken and not tested, and the investigator must document this in the site study', 'records;', 'At the request of, GSK or ViiV Healthcare;', 'The participant requires concurrent prohibited medications during the course of the', 'study. The participant may remain in the study if in the opinion of the Investigator', 'and the medical monitor, such medication will not interfere with the conduct or', 'interpretation of the study or compromise the safety of the participant.', 'Participants must be discontinued from the study for any of the following reasons:', 'Virologic withdrawal criteria as specified in Section 7.1.1 are met', 'Participant is identified as having been mistakenly screened/randomized with', 'exclusionary resistance (see Section 7.1.1)', 'Participant requires substitution or dose modification of DTG, 3TC or any', 'component of CAR. For participants on CAR, a switch from a PI boosted with', 'ritonavir to the same PI boosted with cobicistat (and vice versa) and a switch from', 'lamivudine to emtricitabine (and vice versa) is permitted per protocol.', 'Liver toxicity where stopping criteria specified in Section 7.1.2 are met and no', 'compelling alternate cause is identified', 'Allergic reaction or Rash criteria as described in Section 11.3.1.5 and Section', '11.3.1.6 are met and no compelling alternate cause is identified', 'Renal toxicity as specified in Section 11.3.1.3 are met and no compelling alternate', 'cause is identified', 'Grade 4 clinical or laboratory AE considered causally related to study intervention', 'Pregnancy (intrauterine), regardless of termination status of pregnancy (Section', '8.2.6). As a reminder, females of reproductive potential who change their minds and', 'desire to be pregnant, or who state they no longer are willing to comply with the', 'approved pregnancy avoidance methods, should also be withdrawn from the study.', 'Refer to the Schedule of Activities (SoA) (Section 1.3) for data to be collected at the time', 'of study discontinuation and follow-up and for any further evaluations that need to be', 'completed.', 'All data from the Withdrawal visit will be recorded, as they comprise an essential', 'evaluation that should be done prior to discharging any participant from the study.', 'An', 'in-clinic Follow-Up visit will be conducted 4 weeks after the last dose of study', 'medication for participants with ongoing AEs, serious adverse events (SAEs) regardless', '55']\n\n###\n\n", "completion": "END"}